Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) 123I-QNB SPECT

Journal of Neurology

Volumn 254, Issue 7, 2007, Pages 907-913

  Pakrasi, S ^a   Colloby, S J ^a   Firbank, M J ^a   Perry, E K ^a   Wyper, D J ^b   Owens, J ^c   McKeith, I G ^a   Williams, E D ^d   O'Brien, J T ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

^d SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Molecular imaging; Muscarinic receptors; RCBF; SPECT

Indexed keywords

HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IODOQUINUCLIDINYLBENZILATE I 123; MUSCARINIC M1 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; QUINUCLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HIPPOCAMPUS; HUMAN; IMAGE ANALYSIS; MALE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL ANALYSIS; SUBICULUM; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN MAPPING; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; QUINUCLIDINYL BENZILATE; RECEPTORS, MUSCARINIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34547676184     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-006-0473-8     Document Type: Article

References (40)

1. Araujo DM, Lapchak PA, Robitaille Y, Gauthier S, Quirion R (1988) Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 50:1914-1923
2. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL (1995) Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 64:749- 760
3. Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403
4. Samuel W, Terry RD, DeTeresa R, Butters N, Masliah E (1994) Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia. Arch Neurol 51:772-778
5. White P, Hiley CR, Goodhardt MJ, Carrasco LH, Keet JP, Williams IE, Bowen DM (1977) Neocortical cholinergic neurons in elderly people. Lancet 1:668-671
6. Geula C, Mesulam MM (1996) Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb Cortex 6:165-177
7. Perry E, Court J, Goodchild R, Griffiths M, Jaros E, Johnson M, Lloyd S, Piggott M, Spurden D, Ballard C, McKeith I, Perry R (1998) Clinical neurochemistry: developments in dementia research based on brain bank material. J Neural Transm 105:915-933
8. Geula C, Mesulam MM, Saroff DM, Wu CK (1998) Relationship between plaques, tangles, and loss of cortical cholinergic fibers in Alzheimer disease. J Neuropathol Exp Neurol 57:63-75
9. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2:1457-1459
10. Rinne JO, Laakso K, Lonnberg P, Molsa P, Paljarvi L, Rinne JK, Sako E, Rinne UK (1985) Brain muscarinic receptors in senile dementia. Brain Res 336:19-25
11. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M (1986) Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J Neurochem 46:288-293
12. Shiozaki K, Iseki E, Uchiyama H, Watanabe Y, Haga T, Kameyama K, Ikeda T, Yamamoto T, Kosaka K (1999) Alterations of muscarinic acetylcholine receptor subtypes in diffuse lewy body disease: relation to Alzheimer's disease [see comments]. J Neurol Neurosurg Psychiatry 67:209-213
13. Nordberg A, Winblad B (1986) Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett 72:115-119
14. Aubert I, Araujo DM, Cecyre D, Robitaille Y, Gauthier S, Quirion R (1992) Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 58:529-541
15. Piggott MA, Owens J, O'Brien J, Colloby S, Fenwick J, Wyper D, Jaros E, Johnson M, Perry RH, Perry EK (2003) Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease. J Chem Neuroanat 25:161-173
16. Piggott M, Owens J, O'Brien J, Paling S, Wyper D, Fenwick J, Johnson M, Perry R, Perry E (2002) Comparative distribution of binding of the muscarinic receptor ligands pirenzepine, AF-DX 384, (R,R)-I-QNB and (R,S)-I-QNB to human brain. J Chem Neuroanat 24:211-223
17. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 12:189-198
18. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R (1986) CAMDEX A Standardised Instrument for the Diagnosis of Mental Disorder in the Elderly with Special Reference to the Early Detection of Dementia. Br J Psychiatry 149:698-709
19. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308-2314
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944
21. Lee KS, He XS, Jones DW, Coppola R, Gorey JG, Knable MB, deCosta BR, Rice KC, Weinberger DR (1996) An improved method for rapid and efficient radioiodination of iodine-123-IQNB. J Nucl Med 37:2021-2024
22. Brown D, Chisholm JA, Owens J, Pimlott S, Patterson J, Wyper D (2003) Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with Alzheimer's disease. Eur J Nucl Med Mol Imag 30:296-300
23. Talairach J, Tournoux P (1988) Coplanar stereotactic atlas of the human brain. Thieme, Stuttgart New York
24. Acton PD, Friston KJ (1998) Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. Eur J Nucl Med 25:663-667
25. Chatfield C, Collins AJ (1980) Introduction to multivariate analysis.189- 210
26. Frackowiak RS, Friston KJ, Frith CD, Dolan RJ, Mazziotta JC (1997) Human brain function. In: Academic Press, p 67-70
27. Friston KJ, Worsley KJ, Frackowiak RSJ, Mazziotta JC, Evans AC (1994) Assessing the significance of focal activations using their spatial extent. Hum Brain Map 1:214-220
28. Brett M (1999) The MNI brain and the Talairach Atlas. In:MRC Cognition and Brain Sciences Unit. http://www.mrccbu. cam.ac.uk/Imaging/contents.html
29. Bartenstein P, Minoshima S, Hirsch C, Buch K, Willoch F, Mosch D, Schad D, Schwaiger M, Kurz A (1997) Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. J Nucl Med 38:1095-1101
30. Grossman M, Payer F, Onishi K, D'Esposito M, Morrison D, Sadek A, Alavi A (1998) Language comprehension and regional cerebral defects in frontotemporal degeneration and Alzheimer's disease. Neurology 50:157-163
31. Osimani A, Ichise M, Chung DG, Pogue JM, Freedman M (1994) SPECT for differential diagnosis of dementia and correlation of rCBF with cognitive impairment. Can J Neurol Sci 21:104- 111
32. Holman BL, Gibson RE, Hill TC, Eckelman WC, Albert M, Reba RC (1985) Muscarinic acetylcholine receptors in Alzheimer's disease. In vivo imaging with iodine 123-labeled 3-quinuclidinyl- 4-iodobenzilate and emission tomography. Jama 254:3063-3066
33. Weinberger DR, Gibson R, Coppola R, Jones DW, Molchan S, Sunderland T, Berman KF, Reba RC (1991) The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia. A controlled study with 123IQNB and single photon emission computed tomography. Arch Neurol 48:169-176
34. Kemp PM, Holmes C, Hoffmann S, Wilkinson S, Zivanovic M, Thom J, Bolt L, Fleming J, Wilkinson DG (2003) A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease. J Neurol Neurosurg Psychiatry 74:1567-1570
35. Wyper DJ, Brown D, Patterson J, Owens J, Hunter R, Teasdale E, McCulloch J (1993) Deficits in iodinelabelled 3-quinuclidinyl benzilate binding in relation to cerebral blood flow in patients with Alzheimer's disease. Eur J Nucl Med 20:379-386
36. Claus JJ, Dubois EA, Booij J, Habraken J, de Munck JC, van Herk M, Verbeeten B Jr., van Royen EA (1997) Demonstration of a reduction in muscarinic receptor binding in early Alzheimer's disease using iodine-123 dexetimide single-photon emission tomography. Eur J Nucl Med 24:602-608
37. Boundy KL, Barnden LR, Katsifis AG, Rowe CC (2005) Reduced posterior cingulate binding of I-123 iodo-dexetimide to muscarinic receptors in mild Alzheimer's disease. J Clin Neurosci 12:421-425
38. Yoshida T, Kuwabara Y, Ichiya Y, Sasaki M, Fukumura T, Ichimiya A, Takita M, Ogomori K, Masuda K (1998) Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer's disease patients on 11C-N-methyl-4- piperidyl benzilate-comparison with cerebral blood flow and cerebral glucose metabolism. Ann Nucl Med 12:35-42
39. Zubieta JK, Koeppe RA, Frey KA, Kilbourn MR, Mangner TJ, Foster NL, Kuhl DE (2001) Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET. Synapse 39:275-287
40. Ogawa M, Iida Y, Nakagawa M, Kuge Y, Kawashima H, Tominaga A, Ueda M, Magata Y, Saji H (2006) Change of central cholinergic receptors following lesions of nucleus basalis magnocellularis in rats: search for an imaging index suitable for the early detection of Alzheimer's disease. Nucl Med Biol 33:249-254